United Therapeutics Corporation  

(Public, NASDAQ:UTHR)   Watch this stock  
Find more results for uthr
-0.53 (-0.34%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 152.08 - 156.45
52 week 84.63 - 164.38
Open 154.80
Vol / Avg. 442,148.00/545,225.00
Mkt cap 7.24B
P/E 25.16
Div/yield     -
EPS 6.16
Shares 46.67M
Beta 1.36
Inst. own 111%
Mar 3, 2015
United Therapeutics Corp at Cowen Health Care Conference - 8:00AM EST - Add to calendar
Feb 24, 2015
Q4 2014 United Therapeutics Corp Earnings Release
Feb 24, 2015
Q4 2014 United Therapeutics Corp Earnings Call
Jan 12, 2015
United Therapeutics Corp at JPMorgan Healthcare Conference (Q&A Session)
Jan 12, 2015
United Therapeutics Corp at JPMorgan Healthcare Conference (Presentation)
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 33.47% 26.39%
Operating margin 51.56% 41.82%
EBITD margin - 44.32%
Return on average assets 23.51% 17.12%
Return on average equity 37.47% 26.47%
Employees 706 -
CDP Score - -


United States - Map
+1-301-6089292 (Phone)
+1-301-6089291 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of unique products to address the unmet medical needs of patients. The Company�s therapeutic products and product candidates include: Prostacyclin Analogues, the lead product is Remodulin Injection, for the treatment of pulmonary arterial hypertension (PAH). It is conducting pre-clinical studies of a self-injectable form of treprostinil, which it refers to as TransCon treprostinil; Phosphodiesterase Type 5 (PDE-5) Inhibitor, product Adcirca tablets, a once-daily oral therapy for the treatment of PAH; Monoclonal Antibody (MAb), Ch14.18 MAb for the treatment of neuroblastoma; Glycobiology Antiviral Agent, an alpha-glucosidase inhibitor called UV-4B, for the treatment of dengue; Cell-Based Therapy, the Company developed and commercialized its cell-based product known as PLacental eXpanded (PLX) cells for the treatment of PAH, and Lung Transplantation.

Officers and directors

Martine A. Rothblatt Ph.D., J.D. Chairman of the Board, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Roger Jeffs Ph.D. President, Co-Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Christopher Patusky J.D. Lead Independent Vice Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
John M. Ferrari Ph.D. Chief Financial Officer, Treasurer
Age: 58
Bio & Compensation  - Reuters
David Zaccardelli Pharm.D Chief Operating Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Paul A. Mahon J.D. Executive Vice President, General Counsel, Corporate Secretary
Age: 50
Bio & Compensation  - Reuters
Raymond A. Dwek Non-Independent Director
Age: 72
Bio & Compensation  - Reuters
Katherine J Klein Ph.D Director
Bio & Compensation  - Reuters
Raymond C. Kurzweil J.D. Non-Independent Director
Age: 66
Bio & Compensation  - Reuters
Christopher Causey Independent Director
Age: 51
Bio & Compensation  - Reuters